BWA
PCVX icon

Basecamp Wealth Advisors’s Vaxcyte PCVX Stock Holding History

Basecamp Wealth Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25K Sell
430
-11
-2% -$597 ﹤0.01% 737
2026
Q1 		$25.6K Sell
441
-44
-9% -$2.39K 0.01% 745
2025
Q4 		$22.4K Buy
+485
New +$21.7K ﹤0.01% 756

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Basecamp Wealth Advisors's PCVX Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its Vaxcyte (PCVX) stake by 2.5% in Q2 2026, selling an estimated $597 and leaving 430 shares worth $25K. The position accounts for ﹤0.01% of the portfolio, ranked #737.

Basecamp Wealth Advisors first reported a position in PCVX in Q4 2025 and has held it in 3 quarters since. The position peaked at $25.6K in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Basecamp Wealth Advisors held 430 shares of Vaxcyte worth $25K as of Q2 2026.
  • Basecamp Wealth Advisors sold 11 Vaxcyte shares in Q2 2026, an estimated $597.
  • Vaxcyte made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #737 holding.
  • Basecamp Wealth Advisors first reported a position in Vaxcyte in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's Vaxcyte position peaked at $25.6K in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.